Avenzo Therapeutics to reveal VBC103 Phase 1 results at ESMO Asia 2026
Avenzo's partner VelaVigo will disclose early human safety and efficacy findings for the Nectin-4/TROP2 antibody-drug conjugate VBC103 at ESMO Asia 2026. The presentation could clarify the clinical potential of dual-antigen targeting, while a separate United States study advances in urothelial cancer.